Fluphenazine Hydrochloride

Chorea, Depression, Sedation + 4 more

Treatment

1 FDA approval

20 Active Studies for Fluphenazine Hydrochloride

What is Fluphenazine Hydrochloride

Fluphenazine

The Generic name of this drug

Treatment Summary

Trifluoperazine is a medication used to treat mental disorders such as psychosis. It works in a similar way to chlorpromazine and is used to reduce symptoms like hallucinations, delusions, and agitation.

Fluphenazine Hydrochloride

is the brand name

image of different drug pills on a surface

Fluphenazine Hydrochloride Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Fluphenazine Hydrochloride

Fluphenazine

1987

181

Approved as Treatment by the FDA

Fluphenazine, also known as Fluphenazine Hydrochloride, is approved by the FDA for 1 uses including Schizophrenia .

Schizophrenia

Helps manage Psychosis

Effectiveness

How Fluphenazine Hydrochloride Affects Patients

Fluphenazine is a medication used to treat schizophrenia and other psychosis-related disorders. It is not known to be effective for managing the behavior of people with mental disabilities.

How Fluphenazine Hydrochloride works in the body

Fluphenazine works by blocking certain receptors in the brain related to dopamine. This affects processes like body temperature, wakefulness, and vomiting. It also reduces the release of hormones from the hypothalamus and pituitary gland.

When to interrupt dosage

The measure of Fluphenazine Hydrochloride is contingent upon the diagnosed complaint, including Schizophrenia, Gilles de la Tourette's Syndrome and Sedation therapy. The dosage amount varies, based on the mode of delivery (e.g. Tablet, film coated - Oral or Intramuscular) indicated in the table beneath.

Condition

Dosage

Administration

Depression

, 5.0 mg/mL, 0.5 mg/mL, 2.5 mg, 5.0 mg, 10.0 mg, 1.0 mg, 25.0 mg/mL, 2.5 mg/mL, 2.0 mg, 125.0 mg/mL, 100.0 mg/mL

Solution, concentrate - Oral, Oral, Solution, concentrate, , Elixir - Oral, Tablet, film coated, Intramuscular; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Subcutaneous, Tablet - Oral, Tablet, Intramuscular, Injection, solution - Intramuscular, Liquid, Liquid - Intramuscular; Subcutaneous, Liquid - Intramuscular, Solution, Injection, Injection - Intramuscular; Subcutaneous, Tablet, film coated - Oral, Elixir, Solution - Intramuscular; Subcutaneous

Schizophrenia

, 5.0 mg/mL, 0.5 mg/mL, 2.5 mg, 5.0 mg, 10.0 mg, 1.0 mg, 25.0 mg/mL, 2.5 mg/mL, 2.0 mg, 125.0 mg/mL, 100.0 mg/mL

Solution, concentrate - Oral, Oral, Solution, concentrate, , Elixir - Oral, Tablet, film coated, Intramuscular; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Subcutaneous, Tablet - Oral, Tablet, Intramuscular, Injection, solution - Intramuscular, Liquid, Liquid - Intramuscular; Subcutaneous, Liquid - Intramuscular, Solution, Injection, Injection - Intramuscular; Subcutaneous, Tablet, film coated - Oral, Elixir, Solution - Intramuscular; Subcutaneous

Sedation therapy

, 5.0 mg/mL, 0.5 mg/mL, 2.5 mg, 5.0 mg, 10.0 mg, 1.0 mg, 25.0 mg/mL, 2.5 mg/mL, 2.0 mg, 125.0 mg/mL, 100.0 mg/mL

Solution, concentrate - Oral, Oral, Solution, concentrate, , Elixir - Oral, Tablet, film coated, Intramuscular; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Subcutaneous, Tablet - Oral, Tablet, Intramuscular, Injection, solution - Intramuscular, Liquid, Liquid - Intramuscular; Subcutaneous, Liquid - Intramuscular, Solution, Injection, Injection - Intramuscular; Subcutaneous, Tablet, film coated - Oral, Elixir, Solution - Intramuscular; Subcutaneous

Tourette Syndrome

, 5.0 mg/mL, 0.5 mg/mL, 2.5 mg, 5.0 mg, 10.0 mg, 1.0 mg, 25.0 mg/mL, 2.5 mg/mL, 2.0 mg, 125.0 mg/mL, 100.0 mg/mL

Solution, concentrate - Oral, Oral, Solution, concentrate, , Elixir - Oral, Tablet, film coated, Intramuscular; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Subcutaneous, Tablet - Oral, Tablet, Intramuscular, Injection, solution - Intramuscular, Liquid, Liquid - Intramuscular; Subcutaneous, Liquid - Intramuscular, Solution, Injection, Injection - Intramuscular; Subcutaneous, Tablet, film coated - Oral, Elixir, Solution - Intramuscular; Subcutaneous

Chorea

, 5.0 mg/mL, 0.5 mg/mL, 2.5 mg, 5.0 mg, 10.0 mg, 1.0 mg, 25.0 mg/mL, 2.5 mg/mL, 2.0 mg, 125.0 mg/mL, 100.0 mg/mL

Solution, concentrate - Oral, Oral, Solution, concentrate, , Elixir - Oral, Tablet, film coated, Intramuscular; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Subcutaneous, Tablet - Oral, Tablet, Intramuscular, Injection, solution - Intramuscular, Liquid, Liquid - Intramuscular; Subcutaneous, Liquid - Intramuscular, Solution, Injection, Injection - Intramuscular; Subcutaneous, Tablet, film coated - Oral, Elixir, Solution - Intramuscular; Subcutaneous

Sedation

, 5.0 mg/mL, 0.5 mg/mL, 2.5 mg, 5.0 mg, 10.0 mg, 1.0 mg, 25.0 mg/mL, 2.5 mg/mL, 2.0 mg, 125.0 mg/mL, 100.0 mg/mL

Solution, concentrate - Oral, Oral, Solution, concentrate, , Elixir - Oral, Tablet, film coated, Intramuscular; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Subcutaneous, Tablet - Oral, Tablet, Intramuscular, Injection, solution - Intramuscular, Liquid, Liquid - Intramuscular; Subcutaneous, Liquid - Intramuscular, Solution, Injection, Injection - Intramuscular; Subcutaneous, Tablet, film coated - Oral, Elixir, Solution - Intramuscular; Subcutaneous

Huntington Disease

, 5.0 mg/mL, 0.5 mg/mL, 2.5 mg, 5.0 mg, 10.0 mg, 1.0 mg, 25.0 mg/mL, 2.5 mg/mL, 2.0 mg, 125.0 mg/mL, 100.0 mg/mL

Solution, concentrate - Oral, Oral, Solution, concentrate, , Elixir - Oral, Tablet, film coated, Intramuscular; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Subcutaneous, Tablet - Oral, Tablet, Intramuscular, Injection, solution - Intramuscular, Liquid, Liquid - Intramuscular; Subcutaneous, Liquid - Intramuscular, Solution, Injection, Injection - Intramuscular; Subcutaneous, Tablet, film coated - Oral, Elixir, Solution - Intramuscular; Subcutaneous

Warnings

Fluphenazine Hydrochloride Contraindications

Condition

Risk Level

Notes

Brain Injuries

Do Not Combine

Disease

Do Not Combine

Liver Damage

Do Not Combine

Mental Depression

Do Not Combine

Hypnotics

Do Not Combine

Brain Injuries

Do Not Combine

Coma

Do Not Combine

There are 20 known major drug interactions with Fluphenazine Hydrochloride.

Common Fluphenazine Hydrochloride Drug Interactions

Drug Name

Risk Level

Description

Amisulpride

Major

Fluphenazine may increase the antipsychotic activities of Amisulpride.

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Fluphenazine.

Azelastine

Major

Fluphenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Dacomitinib

Major

The metabolism of Dacomitinib can be decreased when combined with Fluphenazine.

Deutetrabenazine

Major

The risk or severity of adverse effects can be increased when Fluphenazine is combined with Deutetrabenazine.

image of a doctor in a lab doing drug, clinical research

Fluphenazine Hydrochloride Novel Uses: Which Conditions Have a Clinical Trial Featuring Fluphenazine Hydrochloride?

640 active studies are currently in progress to assess the potential of Fluphenazine Hydrochloride to provide relief from Huntington Disease, Sedation therapy and Chorea.

Condition

Clinical Trials

Trial Phases

Sedation therapy

0 Actively Recruiting

Sedation

2 Actively Recruiting

Early Phase 1, Not Applicable

Tourette Syndrome

0 Actively Recruiting

Depression

299 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Huntington Disease

5 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Chorea

0 Actively Recruiting

Schizophrenia

30 Actively Recruiting

Early Phase 1, Not Applicable, Phase 4

Fluphenazine Hydrochloride Reviews: What are patients saying about Fluphenazine Hydrochloride?

5

Patient Review

5/3/2014

Fluphenazine Hydrochloride for Schizophrenia

I've taken this drug twice now, 25mg each time by I.M., and I haven't had any issues. If anything, it's helped me feel more relaxed.

5

Patient Review

8/29/2019

Fluphenazine Hydrochloride for Schizophrenia

Fluphenazine was a great replacement for thiothixene when it was discontinued. I experienced no side effects and found it to be just as effective, if not more so.

5

Patient Review

5/22/2008

Fluphenazine Hydrochloride for Schizophrenia

4.7

Patient Review

11/20/2013

Fluphenazine Hydrochloride for Mental Disorder with Loss of Normal Personality & Reality

I find that this medication is really effective when used in conjunction with lithium. It helps me sleep at night and keeps my mood stable. I haven't had any side effects during the 2+ years I've been on it, (2mg) but when my dr started reducing my dose I had 24 hrs of muscle spasms in my mouth going through withdrawal.

4.7

Patient Review

7/9/2009

Fluphenazine Hydrochloride for Schizophrenia

Another person who reviewed this medication said they experienced muscle stiffness in their mouth, so my doctor recommended Bendryl. If you experience this side effect, talk to your doctor.

3.7

Patient Review

3/20/2009

Fluphenazine Hydrochloride for Schizophrenia

I found that this medicine made me talk in my sleep, and I also experienced muscle stiffness in my mouth. It was a scary feeling - I thought I was going to die!

3.7

Patient Review

12/16/2009

Fluphenazine Hydrochloride for Mental Disorder with Loss of Normal Personality & Reality

I started taking this medication and the first night I had some really bad nightmares. If anyone else has experienced this, please let me know in the comments below.

3.7

Patient Review

10/28/2007

Fluphenazine Hydrochloride for Mental Disorder with Loss of Normal Personality & Reality

2.3

Patient Review

6/21/2015

Fluphenazine Hydrochloride for Schizophrenia

Unfortunately, I had to stop taking this medicine because it caused me intense restlessness.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about fluphenazine hydrochloride

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does fluphenazine do to the brain?

"This medication is used to treat symptoms of schizophrenia. Fluphenazine belongs to a class of medications called phenothiazines. It works by affecting the balance of natural chemicals in the brain."

Answered by AI

Does fluphenazine have side effects?

"The following effects may occur: drowsiness, lethargy, dizziness, lightheadedness, nausea, loss of appetite, sweating, dry mouth, blurred vision, headache, and constipation. If you experience any of these effects, contact your doctor or pharmacist."

Answered by AI

What is fluphenazine hydrochloride used for?

"Fluphenazine is an antipsychotic medication used to treat schizophrenia and psychotic symptoms such as hallucinations, delusions, and hostility. It can also be prescribed for other uses; so if you're curious, ask your doctor or pharmacist for more information."

Answered by AI

Is fluphenazine a sedative?

"Fluphenazine is a potent phenothiazine neuroleptic used to treat schizophrenia in humans. In horses, it is used off-label for its anxiolytic and long-acting sedative effects."

Answered by AI

Clinical Trials for Fluphenazine Hydrochloride

Image of Stanford University School of Medicine in Stanford, United States.

BEAR Program for Suicidal Thoughts

18 - 75
Female
Stanford, CA

The current study aims to test the feasibility of a new form of group therapy for women who have a history of interpersonal trauma and current suicidal ideation. The Building Empowerment and Resilience (BEAR) Therapeutic group has been adapted for women who have experienced trauma and have current suicidal ideation. It incorporates psychological skills, psychoeducation about trauma and gender-based violence, and physical self-defense training, all within a therapeutic process. It will be implemented with women who have experienced interpersonal trauma (physical, sexual, or emotional abuse/neglect) and experience various mental health difficulties, including suicidal ideation. We aim to assess the feasibility to recruit and implement the BEAR group. Our ultimate aim is to assess whether the program can effect self-efficacy and suicidal ideation.

Waitlist Available
Has No Placebo

Stanford University School of Medicine

Jennifer Keller, PhD

Image of Western Psychiatric Hospital/University of Pittsburgh in Pittsburgh, United States.

Sleep and Circadian Interventions for Suicide

18 - 25
All Sexes
Pittsburgh, PA

The purpose of this study is to examine the extent to which delivering sleep and circadian focused interventions in addition to evidenced based psychiatric care for depression and suicide risk may contribute to decreasing suicide risk among high risk young adults. Investigators will evaluate three interventions targeting sleep in acutely suicidal college students enrolled in intensive outpatient treatment. Participants will be randomly assigned to one of three intervention groups: 1. Triple Chronotherapy (TCT)+ Transdiagnostic Sleep and Circadian Intervention (TSC) 2. Transdiagnostic Sleep and Circadian Intervention (TSC) 3. Sleep Feedback (SF) Participants will be followed for 6 months with primary outcome domains of suicidal thoughts and behaviors and depression evaluated by blinded clinicians at short (Days 1-4 of intervention), medium (2 months) and long (6 month) term intervals.

Waitlist Available
Has No Placebo

Western Psychiatric Hospital/University of Pittsburgh

Tina Goldstein, PhD

Image of University of South Florida in Tampa, United States.

WeACT Program for Caregivers of People With Dementia

18+
All Sexes
Tampa, FL

The goal of this clinical trial is to learn whether WeACT, a self-paced, web-based program, is feasible and helpful for adult family caregivers of a relative living with dementia. WeACT is based on acceptance and commitment therapy (ACT), which teaches skills to handle difficult thoughts and feelings and take steps toward what matters most. The main questions this study aims to answer are: * Can caregivers complete WeACT as planned? * Do caregivers show improvements in mental health and coping after using WeACT? * What are caregivers' experiences with the program, and what suggestions do they have to improve it? Participants will: * Complete six self-paced weekly online modules and use the daily practice section during the program. * Complete online questionnaires before starting and after completing the program. * Take part in one online interview about their experience.

Waitlist Available
Has No Placebo

University of South Florida

Areum Han

Image of Fred Hutch/University of Washington Cancer Consortium in Seattle, United States.

Psilocybin Therapy for Anxiety and Depression in Cancer

18 - 85
All Sexes
Seattle, WA

This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) or with hematologic cancers for which no treatment is currently available (incurable). For patients with metastatic, incurable cancer, unrelieved anxiety and existential distress can cause profound suffering. Psilocybin therapy can relieve anxiety and existential distress by disrupting patterns of thinking that contribute to anxiety and depression. Psilocybin is a substance being studied in the treatment of anxiety or depression in patients with cancer. In this study, a pharmaceutical grade of psilocybin will be used that has been approved by the FDA for research, provided by Filament Health. Psilocybin acts on the brain by resetting the brain's activity and increasing connections between brain regions, particularly those involved in mood regulation and self-perception. In this study psilocybin is combined with structured discussions and reflections that enable patients to have new insights about their situation. In a prior study, group retreat psilocybin therapy was proven to be safe and this study tests a refined dosing regimen for symptoms of anxiety and depression in patients with metastatic solid tumors or incurable hematologic malignancies.

Phase 2
Waitlist Available

Fred Hutch/University of Washington Cancer Consortium

Anthony Back, MD

Have you considered Fluphenazine Hydrochloride clinical trials?

We made a collection of clinical trials featuring Fluphenazine Hydrochloride, we think they might fit your search criteria.
Go to Trials
Image of Seaway Valley Community Health Centre (Cardiac Rehab Program) in Cornwall, Canada.

FRAME for Heart Failure

18+
All Sexes
Cornwall, Canada

Heart failure is a high-risk, chronic condition that impacts patients' mental health. Approximately 50% of heart failure patients experience comorbid mental health conditions, such as stress, depression and anxiety, which affect their day-to-day lives. Despite this interconnection, the integration of mental health awareness and support into cardiac care remains limited. To address this gap, the FRAME (Foundation, Recognition, Awareness, Management, Engagement) intervention was co-designed by researchers, healthcare providers, health system decisionmakers, and patient partners. This pilot study evaluates the feasibility of implementing the FRAME intervention in pilot clinical sites within two health regions in Ontario, Canada, including team-based family medicine clinics, cardiac rehabilitation/specialist clinics, and emergency departments. Utilizing a pretest-posttest hybrid 1 model intervention design, this study evaluates process indicators and patient-focused outcomes through surveys and semi-structured qualitative interviews. Findings from this study will inform a future large scale cohort study and scalable integration of the FRAME tool into existing cardiac care pathways to enhance mental health awareness and support among heart failure patients.

Recruiting
Has No Placebo

Seaway Valley Community Health Centre (Cardiac Rehab Program) (+8 Sites)

Image of Lincoln Middle School in Cottage Grove, United States.

Behavioral Interventions for Depression in Students

Any Age
All Sexes
Cottage Grove, OR

The goal of this clinical trial is to learn if two behavioral interventions work to reduce office disciplinary referrals, improve attendance, and reduce depression and anxiety in 7th grade students. This project combines two evidence-based programs-the Inclusive Skill-building Learning Approach (ISLA) for school-wide discipline reform and the Family Check-Up Online (FCU-O) for family-centered support-in an adaptive design to examine the unique and additive effects of these interventions on these child behavior outcomes. The main questions it will answer are: 1. What is the relative efficacy of ISLA vs. School-as-Usual? 2. What is the optimal sequencing of these interventions? 3. Which overall sequence of intervention strategies was most effective? Researchers will compare 6 combinations of these interventions to see which combination and sequencing provides the best student outcomes. School personnel participating in the project will be trained to implement the two interventions at their school. They will answer surveys in the fall, winter, and spring of their year of participation. Parent and Youth participants will complete surveys at baseline and then again 6 months and 12 months later.

Waitlist Available
Has No Placebo

Lincoln Middle School (+12 Sites)

Beth Stormshak, PhD

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Living Well Program for Anxiety in Breast Cancer

18+
Female
Los Angeles, CA

The goal of this study is to evaluate the efficacy and cost-effectiveness of the Living Well Program, a digital therapeutic application with telecoaching support, in breast cancer patients with moderate-to-severe anxiety. The main question the study aims to answer is: does digital cognitive-behavioral therapy-based interventions decrease the overall healthcare costs of patients with stage II to IV breast cancer? The study has one group of participants who will use the Living Well app and telecoaching support. This group will be compared to retroactively matched controls. Over 3 months, patients will complete 21 mental health modules and 5 telecoaching sessions. In the following 3 months, they will complete any outstanding telecoaching sessions and modules while still being monitored, even if they finished all modules and sessions in the first 3 months. The 6 months after that will be the follow-up phase. They will still have access to the Living Well app and may continue to use it, and they will complete the same assessment questionnaires as baseline to identify any changes in their overall mental health.

Waitlist Available
Has No Placebo

Cedars-Sinai Medical Center

Scott Irwin, MD

Have you considered Fluphenazine Hydrochloride clinical trials?

We made a collection of clinical trials featuring Fluphenazine Hydrochloride, we think they might fit your search criteria.
Go to Trials
Image of Mayo Clinic in Florida in Jacksonville, United States.

Virtual Reality for Cancer

18 - 90
All Sexes
Jacksonville, FL

This clinical trial tests the safety, tolerability, and effectiveness of a virtual reality intervention to improve psychological symptom burden for cancer patients undergoing treatment. Virtual reality (VR) is a technology that allows users to experience and interact with three-dimensional, computer-generated environments that simulate the real world or imagined settings. The VR intervention consists of a preloaded with immersive environments designed to engage the senses through simulated sights and sounds. This may include a walk through of a serene forest, exploring vibrant coral reefs, swimming with dolphins, or standing at the base of a majestic waterfall. These environments are created to provide a relaxing and engaging experience. Completing the VR intervention may be a safe and effective way to improve quality of life, reduce anxiety, enhance focus, and promote healthy living for cancer patients undergoing treatment.

Recruiting
Has No Placebo

Mayo Clinic in Florida

Juan C. Cardenas Rosales, MD

Image of University of California, Los Angeles in Los Angeles, United States.

Virtual Reality Reward Training for Depression

18+
All Sexes
Los Angeles, CA

The purpose of this study is to compare the effects of enhanced Virtual Reality-Reward Training (eVR-RT) with an active control condition, Virtual Reality-Memory Training (VR-MT), on positive affect and other clinical symptoms. Enhanced VR-Reward Training is a novel intervention aimed at enhancing savoring of positive experiences among individuals with depression and low positive affect through guided imaginal recounting following immersion in positive VR experiences. The current study tests an enhanced version of this training using improved virtual reality technology. Target enrollment is 80 participants with low positive affect, depression, and impaired functioning, who are at least 18 years old, who will be randomly assigned to 7 weeks of either enhanced Virtual Reality-Reward Training (VR-RT) or Virtual Reality-Memory Training (VR-MT). Participants will complete in-person VR sessions, laboratory assessments, self-report questionnaires as part of the study. A subset of 8 participants randomly assigned to VR-RT will complete fMRI scans and EMA surveys. The total length of participation is around 3 months.

Phase 2
Recruiting

University of California, Los Angeles

Have you considered Fluphenazine Hydrochloride clinical trials?

We made a collection of clinical trials featuring Fluphenazine Hydrochloride, we think they might fit your search criteria.
Go to Trials